Bioeq IP AG

Bioeq IP AG is located in Zug, Switzerland on Poststrasse 18. Bioeq IP AG is rated 3 out of 5 in the category biotechnology company in Switzerland. Bioeq AG is a biopharmaceutical joint venture between the leading Polish pharmaceutical company Polpharma and the Strüngmann family’s investment company based in Zürich, Switzerland. Bioeq IP AG licenses, develops and commercializes biological successor products of successful biopharmaceuticals, called biosimilars. FYB201 is currently the most advanced biosimilar program of Bioeq having demonstrated comparable efficacy to its reference medicinal product Lucentis® in patients with neovascular age-related macular degeneration (nAMD) in the COLUMBUS-AMD trial. All required clinical studies and registration activities are conducted by our subsidiary, Bioeq GmbH based in Holzkirchen, Germany, on behalf of Bioeq AG.